ASTRAZENECA PLC

AZN’s shares dip 0.03% while maintaining a GBX 350.6bn market cap—find out how its diversified pharma portfolio keeps investors focused.

Explore AstraZeneca’s slight 0.03 % dip—deep dive into its market cap, liquidity, and pipeline resilience, and why investors should watch earnings & approvals for a potential rebound.

On 21 Mar 2026, AstraZeneca shares rose 1.76%, closing at £12,612.20. The pharma giant’s 2026 outlook focuses on cancer therapy R&D, AI‑driven trials and strong market growth.